Healthcare & Life Sciences

National Institute of Dental and Craniofacial Research Advisory Council Meeting Notice

NIH's National Institute of Dental and Craniofacial Research announces a meeting of the National Advisory Dental and Craniofacial Research Council on May 19-20, 2026, in Bethesda, MD and virtual format. The closed session on May 19 will review grant applications; the open session on May 20 will include the Director's report and concept clearances. A backup meeting is scheduled for July 9, 2026.

National Institute of Neurological Disorders and Stroke Council Meeting Notice

The NIH National Institute of Neurological Disorders and Stroke has announced a public meeting of the National Advisory Neurological Disorders and Stroke Council on May 20, 2026, from 10:00 a.m. to 5:00 p.m. The virtual meeting will include reports from the Acting Director, program updates on HEAL and Small Business programs, and an overview of intramural activities. Interested persons may submit written comments to the Contact Person at least 10 days in advance of the meeting.

NCATS Advisory Council Meeting Notice May 21-22

The NIH National Center for Advancing Translational Sciences (NCATS) has published notice of its Advisory Council meeting scheduled for May 21-22, 2026. The closed session on May 21 will review grant applications, while the open session on May 22 will cover the Center Director's report, program updates, and concept clearances. The meeting will be held at NCI Shady Grove in Rockville, MD, with virtual access available.

NIEHS Partially Closed Meeting Notice - National Advisory Environmental Health Sciences Council

NIEHS published notice of a partially closed meeting of the National Advisory Environmental Health Sciences Council on June 24, 2026. The meeting includes open sessions on microplastics research, environmental health sciences programs, and health/weather research coordination. A closed session from 4:00-6:00 p.m. will review grant applications under FOIA exemption provisions. Interested persons may submit written comments or request to present oral comments to the committee.

Establishing Impurity Specifications for Antibiotics Draft Guidance

FDA announced availability of draft guidance titled 'Establishing Impurity Specifications for Antibiotics,' providing recommendations for establishing specifications for organic impurities in antibiotics manufactured by fermentation and semi-synthesis. The draft guidance applies to antibiotic drugs subject to approval under NDAs, ANDAs, and associated type II drug substance DMFs, as well as OTC monograph antibiotic drugs. Comments are due by June 22, 2026.

Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators

FDA announced draft guidance providing a proposed compliance policy for respirators approved by CDC NIOSH under 42 CFR part 84, including surgical N95 respirators, PAPRs, reusable elastomeric respirators, and FFRs for general public use during public health emergencies. Once finalized, the guidance is intended to facilitate more efficient and effective use of resources consistent with least burdensome device policies.

Potential New Indication for Testosterone Replacement Therapy

FDA announced it has reviewed published literature suggesting testosterone replacement therapy (TRT) may be safe and effective for treating low libido in men with decreased libido associated with idiopathic hypogonadism. The Agency encourages holders of approved TRT new drug applications to contact FDA by April 30, 2026, for information on submitting a supplemental NDA for this potential new indication.

GEN-AL-RF Trial: Genicular Nerve RF Ablation vs Alcohol Neurolysis for Knee Osteoarthritis Pain

The NIH ClinicalTrials.gov registry has published NCT07537335, a randomized controlled trial comparing genicular nerve radiofrequency ablation to neurolytic alcohol injection for managing chronic knee pain in osteoarthritis patients. The 6-month study will assess pain intensity using the Numeric Rating Scale, physical function via WOMAC scores, and quality of life through SF-12 metrics. Results aim to provide comparative effectiveness evidence for these interventional pain management techniques.

Sintilimab Plus Lenvatinib Phase 3 Trial for Oligo-Extrahepatic Metastatic Hepatocellular Carcinoma

The NIH ClinicalTrials.gov registry published a Phase 3 study (NCT07537946) evaluating sintilimab plus lenvatinib with or without consolidative therapy in patients with oligo-extrahepatic metastatic hepatocellular carcinoma. The randomized 1:1 trial enrolls participants who achieved disease control after 4 induction cycles. The primary endpoint is overall survival.

EENC Clinical Trial: 162 Mother-Baby Pairs, Shaikh Zayed Hospital, Pakistan

NIH ClinicalTrials.gov registered study NCT07535684 examining Early Essential Newborn Care (EENC) versus routine postnatal care. The single-center trial enrolled 162 mother-baby pairs at Shaikh Zayed Hospital, Rahim Yar Khan, Pakistan. EENC interventions include immediate drying, skin-to-skin contact, delayed cord clamping, thermal care, and breastfeeding initiation within one hour. The study assesses newborn outcomes including early breastfeeding, exclusive breastfeeding at 7 days, hypothermia, hypoglycemia, NICU admission, and maternal outcomes.

Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases

NIH ClinicalTrials.gov has registered NCT07537959, a randomized trial evaluating whether adding primary tumor resection to standard immune-based systemic therapy improves survival in hepatocellular carcinoma patients with extrahepatic metastases. The study will enroll approximately 252 participants and measure overall survival as the primary endpoint.

Benmelstobart Plus Anlotinib Combined With SBRT for Hepatocellular Carcinoma

NIH ClinicalTrials.gov registered Phase 2 trial NCT07537777 evaluating Benmelstobart plus anlotinib combined with stereotactic body radiation therapy (SBRT) in patients with oligometastatic hepatocellular carcinoma who have failed first-line targeted therapy. The prospective, single-arm, multicenter study will assess progression-free survival, objective response rate, disease control rate, overall survival, and treatment safety. Eligible patients receive anlotinib 10mg on days 1-14 every 3 weeks plus Benmelstobart 1200mg on day 1 every 3 weeks combined with SBRT.

Clinical Trial Evaluating Moxibustion for Cold-Syndrome Allergic Rhinitis

NIH's ClinicalTrials.gov has registered a new interventional study (NCT07537439) evaluating the adjunctive effects of mild moxibustion combined with fluticasone propionate (100 mcg) for treating cold-syndrome allergic rhinitis. The randomized trial will assess outcomes including symptom relief, quality of life, and work productivity in patients with IgE-mediated allergic rhinitis. Estimated study completion date is April 17, 2026.

Effects of Music During Walking on Pain and Muscle Activation in People With Chronic Pain Due to Knee Osteoarthritis

NIH registered a new clinical trial on ClinicalTrials.gov (NCT07537114) to study the effects of rhythmic auditory stimulation—walking with music versus walking with a metronome versus walking without sound—on pain and muscle activation in individuals with chronic knee osteoarthritis. The trial will enroll participants receiving one of three interventions: rhythmic auditory stimulation with music, rhythmic auditory stimulation with a metronome, or a control group with no auditory cueing.

SEHAT Virtual Oral Health Promotion for School Adolescents in Pakistan

NIH registered clinical trial NCT07536958 on ClinicalTrials.gov, a cluster-randomized trial evaluating the SEHAT virtual oral health promotion program among school adolescents in Pakistan. The trial will compare virtual SEHAT sessions delivered via Zoom against conventional in-person oral health education and a control group, assessing outcomes including toothbrushing behavior, plaque scores, gingival scores, and oral health knowledge.

Phase I Study: Itraconazole Effect on Pharmacokinetics of HS-10506

The NIH ClinicalTrials.gov registry has registered Phase I clinical trial NCT07535970, a single-center, open-label, fixed-sequence, self-controlled study evaluating the effect of itraconazole (a CYP3A inhibitor) on the pharmacokinetics of HS-10506 tablets in healthy Chinese adult participants. The trial is categorized as Phase 1 and is expected to begin on April 17, 2026.

FDA Denies Citizen Petition FDA-2025-P-3263 from George W. Murgatroyd III

FDA CDER issued a final response letter denying citizen petition FDA-2025-P-3263 submitted by George W. Murgatroyd III. The petition was denied by the Center for Drug Evaluation and Research. No additional details are available as the document attachments contain personally identifiable information and are not publicly accessible.

Variance Approval to VarsIQ Media

The FDA Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to VarsIQ Media. Variances are exemptions or waivers from specific regulatory requirements under the Federal Food, Drug, and Cosmetic Act. This approval modifies the applicable regulatory requirements for VarsIQ Media, allowing deviation from certain standard CDRH requirements.

FDA Center for Tobacco Products Files Complaint FDA-2026-H-3876

The FDA Center for Tobacco Products (CTP) filed a formal complaint (FDA-2026-H-3876-0001) on April 16, 2026. The complaint document is available as an attachment on Regulations.gov. No additional details about the specific allegations, parties involved, or requested relief are accessible in the available metadata.

FDA Complaint FDA-2026-H-3613 Closed - No Documents Available

The FDA posted a complaint record (FDA-2026-H-3613) on April 17, 2025. The complaint was filed by the Center for Tobacco Products (CTP) and has been closed. No documents are available for public review or download. This is a procedural record indicating closure of an unspecified complaint matter.

Arius Recordings LLC Variance Application

FDA's Center for Devices and Radiological Health (CDRH) received a variance application from Arius Recordings LLC. The application seeks relief or exemption from specific FDA regulatory requirements under 21 CFR. No documents are currently available for public viewing, and the application remains under agency review.

VarsIQ Media Ohio Variance Application - CDRH

FDA's Center for Devices and Radiological Health (CDRH) received a variance application from VarsIQ Media seeking relief from specific FDA regulatory requirements. The application was filed under docket FDA-2026-V-3708-0001 in Ohio. No supporting documents are currently available for review on the regulatory portal. This filing represents a request for FDA to exercise regulatory flexibility under applicable medical device regulations.

Qualitative Data Research Clearance Extension, OMB Control No. 0910-0891

The FDA published a notice under the Paperwork Reduction Act announcing an opportunity for public comment on extending OMB Control Number 0910-0891, the Generic Clearance for Qualitative Data to Support Social and Behavioral Research. The clearance covers submissions for qualitative data to support research related to food, dietary supplements, cosmetics, and animal food and feed. Comments must be submitted by June 16, 2026.

FDA CTP Complaint Filed and Closed

FDA's Center for Tobacco Products (CTP) filed a complaint on April 16, 2026, which has since been closed. The document record indicates only that a complaint was filed and subsequently closed, with the full complaint content not available in the regulatory docket. No additional details regarding the nature of the complaint, parties involved, or any resulting enforcement actions are provided in the available metadata.

Animal Generic Drug User Fee Act Reauthorization; Public Meeting and Comment Request

FDA announces a virtual public meeting on May 27, 2026 regarding the Animal Generic Drug User Fee Act (AGDUFA) reauthorization and requests public comments through December 1, 2027. The AGDUFA program, which funds FDA's review of generic animal drug submissions, expires September 30, 2028 without new legislation. FDA is soliciting input on program performance and suggestions for the next authorization.

FDA DMB Acknowledgment Letter to VIP Lighting NWA

FDA's Center for Devices and Radiological Health (CDRH) issued an acknowledgment letter to VIP Lighting NWA regarding submission FDA-2026-V-3710. The document serves as administrative confirmation of receipt of a filing, though the specific submission details are not publicly viewable in the available record. No regulatory obligations, deadlines, or penalties are stated in the acknowledgment.

Methods and Systems for Determining Optimal Decision Time Related to Embryonic Implantation

USPTO granted patent US12591781B2 to Fairtility Ltd. covering AI and machine learning methods and systems for analyzing time-lapse images of developing embryos to predict embryo viability and determine optimal timing for in-vitro fertilization embryo transfer/implantation. The patent covers morpho-kinetic signature analysis from fertilization through blastulation stages. The patent includes 26 claims and is classified under CPC codes in the G16H health informatics range.

Redirect Health Patent Integrates Healthcare Data Using AI

USPTO granted Patent US12591937B1 to Redirect Health, Inc. on March 31, 2026. The patent covers systems for integrating healthcare data from multiple sources using AI networks to generate predictive outputs. The system incorporates multifaceted authorization to access data from various databases and integrate them into a single data warehouse for predictive analysis.

Post-Discharge Monitoring Threshold Mechanism Patent

USPTO granted Patent US12592142B2 to Koninklijke Philips N.V. covering a mechanism for setting time-dependent thresholds for post-discharge monitoring of target subjects. The patent includes 20 claims and was filed on July 19, 2022.

AI Medical Care Coordination Patent, 24 Claims

The USPTO granted patent US12592299B2 to Care Coordination Systems, LLC on March 31, 2026, covering an AI system for coordinating medical care with 24 claims. The patent describes a system including a hub computing device, data collection for patient and provider information, a graphical user interface for real-time gap analysis, and a neural network providing predictive suggestions. Patent grants establish enforceable intellectual property rights.

Rural Health Network Development Planning Program Performance Measures OMB Revision

HRSA submitted an Information Collection Request to OMB for review and approval under the Paperwork Reduction Act of 1995. The agency seeks public comments by May 20, 2026, on revised performance measures for the Rural Health Network Development Planning Program. The proposed revision reduces the total number of measures from 24 to 15, consolidating sections into 'Capacity/Organizational Information' and 'Sustainability.' Estimated annual burden is 281.25 hours across 25 respondents at 11.25 hours per response.

Effect of Simulation-Based Vaginal Examination Training on Anxiety, Confidence, and Skills in Midwifery Students

NIH's ClinicalTrials.gov registered a randomized controlled quasi-experimental study (NCT07535255) investigating the effects of simulation-based vaginal examination training on skill performance, anxiety, and satisfaction in 67 third-year midwifery students at a state university in Turkey. Results showed simulation training significantly reduced state anxiety in both clinical and laboratory groups (p<0.001) and laboratory group students demonstrated improvements in satisfaction and self-confidence (p<0.05). Clinical group students achieved significantly higher vaginal examination skill scores compared to the laboratory group (p<0.001).

Microbiota in OAB, DUI Children, Healthy Controls Compared

NIH has registered observational study NCT07535619 on ClinicalTrials.gov to investigate whether voided urinary, perineal/preputial, and fecal microbiota differ between children with Overactive Bladder (OAB) and Daytime Urinary Incontinence (DUI) compared to age- and gender-matched healthy controls. The study will also assess whether microbiota composition varies by DUI severity and changes throughout treatment.

Phase 2 Leucine Diet Trial Combined With Chemoimmunotherapy for Advanced Gastric Cancer

NIH ClinicalTrials.gov registered a Phase 2 study (NCT07537348) evaluating a leucine-restricted diet combined with chemotherapy and immunotherapy in patients with advanced gastric cancer. The trial will assess safety, tolerability, tumor response rates, and 1-year survival outcomes. No compliance obligations or regulatory actions are imposed by this registry entry.

Leukemia Stem Cell-based Assay to Predict Relapse and Survival in AML Patients With MLL-Rearrangement

NIH's ClinicalTrials.gov has registered an observational study (NCT07537738) examining whether leukemia stem cell detection via multiparameter flow cytometry can predict relapse in acute myeloid leukemia patients with MLL-rearrangement. The study will detect leukemia stem cells alongside minimal residual disease monitoring using bone marrow samples. Participants are AML patients undergoing regular medical care who will have stem cell detection performed concurrently with their existing MRD testing protocols.

Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion

NIH registered a Phase 3 clinical trial (NCT07537933) to evaluate whether immediate intra-arterial tirofiban after complete recanalization improves recovery in adults with acute ischemic stroke caused by anterior circulation large-vessel occlusion. The trial will enroll approximately 520 participants and compare tirofiban treatment with no tirofiban, measuring good functional outcome at 90 days and symptomatic intracranial hemorrhage risk. Primary completion is expected April 17, 2026.

Prospective Exploration of Vascular Complications Associated With Immune Checkpoint Inhibitors

NIH registered an observational study (NCT07535944) on ClinicalTrials.gov to explore vascular complications associated with immune checkpoint inhibitors (ICIs). The study will evaluate the vascular impact of ICIs such as nivolumab, pembrolizumab, and atezolizumab in cancer patients. ICIs have been linked to immune-mediated toxicities affecting various organ systems, including the cardiovascular system, though vascular complications remain poorly understood.

Expanded Access Program for Leronlimab in Metastatic TNBC

NIH's ClinicalTrials.gov registered an Expanded Access Program for investigational leronlimab (PRO 140) in metastatic triple-negative breast cancer, offering a pathway for patients lacking satisfactory treatment options and unable to enroll in clinical trials. The observational, open-label study documents program eligibility, interventions, and study design. No new compliance obligations are created for sponsors, healthcare providers, or patients.

Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children

NIH registered Phase 3 clinical trial NCT07535749 evaluating myopia progression control using MiSight 1 Day (CooperVision) and Abiliti 1-Day (Johnson & Johnson VisionCare) contact lenses in New Zealand Chinese children. The 6-month randomized controlled paired-eye study will enroll participants at Auckland Myopia Clinic with assessments at baseline, 2 weeks, 3 months, and 6 months.

VENEZE Peptide Hair Serum vs 2% Minoxidil for Androgenetic Alopecia

NIH registered a randomized, double-blind Phase 4 clinical trial (NCT07536100) comparing VENEZE peptide hair serum to topical 2% minoxidil in approximately 300 patients with androgenetic alopecia. Participants will be assessed for changes in hair density, hair thickness, and treatment tolerability over the study period. The trial aims to evaluate whether a peptide-based serum offers a viable alternative to standard minoxidil therapy.

Baricitinib Phase 1b/2 Trial for Post-HSCT Persistent Thrombocytopenia

NIH registered a Phase 1b/2 clinical trial (NCT07535645) on ClinicalTrials.gov studying baricitinib in patients with thrombopoietin-receptor-agonist-refractory persistent thrombocytopenia following allogeneic hematopoietic stem cell transplantation. The prospective, open-label trial will evaluate safety and efficacy profiles of the JAK inhibitor intervention.

Prophylactic Anti-epileptic Regimen in Traumatic Brain Injury

NIH registered an observational clinical trial (NCT07535736) evaluating the effectiveness and safety of anti-epileptic drugs in preventing early and late post-traumatic seizures among patients with traumatic brain injury. The study will assess antiepileptic efficacy and safety outcomes in this patient population.

Lidocaine Spray for Postoperative Shoulder Pain in Laparoscopic Surgery

ClinicalTrials.gov registered a randomized controlled trial (NCT07537127) at Peking Union Medical College Hospital evaluating 0.08% lidocaine spray for postoperative shoulder pain in 100 patients undergoing single-port laparoscopic gynecological surgery. The experimental group receives 50ml lidocaine sprayed on bilateral subdiaphragmatic regions; the control group receives standard ERAS protocol. Primary endpoint is NRS pain score at 6 hours postoperatively. Estimated primary completion date is April 17, 2026.

Qualitative Study of Care Perceptions in Chemotherapy Patients

NIH registered an observational qualitative study (NCT07536945) on individualized care perceptions among outpatient chemotherapy patients at Yalova Training and Research Hospital in Turkey. The study will interview 10 to 20 participants over age 18 to understand how personalized nursing care affects symptom management and treatment adherence. Research will be conducted from May 2026 through April 2027.

Observational Falls Validation Study for Traumatic Brain Bleeding

NIH registered an observational study (NCT07536906) to validate a rapid bedside decision rule guiding emergency physicians on when older adults should receive brain scans to diagnose traumatic brain bleeding. The study addresses falls in adults over 65, which result in 500,000 Canadian emergency department visits annually. Researchers will assess whether the clinical decision rule effectively identifies patients requiring imaging for intracranial bleed detection.

Phase 4 Adenosine Pre-Medication in Primary PCI Randomized Control Trial

NIH registered a Phase 4 clinical trial (NCT07536802) evaluating adenosine pre-medication versus standard care in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction patients. The randomized controlled trial aims to assess impact on slow flow/no-reflow phenomenon incidence. The trial is registered on ClinicalTrials.gov.

NCT07535723: Botulinum Toxin and GON Block for Chronic Migraine

A new randomized controlled trial (NCT07535723) was registered on ClinicalTrials.gov evaluating the combination of OnabotulinumtoxinA (Botox) injections with Greater Occipital Nerve (GON) block versus single therapy for chronic migraine patients. The trial will assess improvements in headache frequency, severity, and quality of life. Enrollment target and sponsor details were not specified in the registration record.

Effect of Low-Power Laser Therapy on Pain and Functional Outcomes in Patients With Thoracic Outlet Syndrome

NIH's ClinicalTrials.gov registered a new randomized controlled study (NCT07535853) evaluating low-power laser therapy combined with physical therapy versus conventional treatment alone for thoracic outlet syndrome patients. The trial aims to determine whether adding laser therapy provides superior pain relief and improves daily physical functions. The study carries an anticipated start date of April 17, 2026.

Phase 4 Dulaglutide Triple Therapy for T2DM Chronic Kidney Disease

A Phase 4 clinical trial (NCT07537088) has been registered on ClinicalTrials.gov evaluating dulaglutide as add-on therapy for Chinese adults with Type 2 Diabetes and Chronic Kidney Disease. The 26-week randomized study will assess whether adding dulaglutide to existing SGLT2 inhibitor plus finerenone therapy provides additional kidney protection. Participants must have been on stable combination therapy for at least 3 months before enrollment.

Phase I/II Clinical Trial for HS_SW01 Cells Injection in Systemic Sclerosis

The National Institutes of Health registered a Phase I/II clinical trial (NCT07535931) on ClinicalTrials.gov to evaluate the safety, tolerability, pharmacokinetics, and immunological profile of HS_SW01 human umbilical cord mesenchymal stem cell injection in patients with systemic sclerosis. The single-arm, open-label trial will enroll participants who meet specified inclusion and exclusion criteria following informed consent. No regulatory approvals or compliance deadlines are established by this registration notice.